KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Moderna (MRNA) Operating Expenses (2017 - 2025)

Historic Operating Expenses for Moderna (MRNA) over the last 9 years, with Q3 2025 value amounting to $1.3 billion.

  • Moderna's Operating Expenses fell 3395.45% to $1.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 billion, marking a year-over-year decrease of 2674.3%. This contributed to the annual value of $7.2 billion for FY2024, which is 3523.05% down from last year.
  • Moderna's Operating Expenses amounted to $1.3 billion in Q3 2025, which was down 3395.45% from $1.0 billion recorded in Q2 2025.
  • Moderna's 5-year Operating Expenses high stood at $3.8 billion for Q3 2023, and its period low was $671.0 million during Q1 2021.
  • In the last 5 years, Moderna's Operating Expenses had a median value of $1.8 billion in 2022 and averaged $1.9 billion.
  • As far as peak fluctuations go, Moderna's Operating Expenses skyrocketed by 58359.79% in 2021, and later plummeted by 4972.68% in 2024.
  • Over the past 5 years, Moderna's Operating Expenses (Quarter) stood at $1.8 billion in 2021, then surged by 94.56% to $3.5 billion in 2022, then dropped by 19.95% to $2.8 billion in 2023, then fell by 21.14% to $2.2 billion in 2024, then tumbled by 42.31% to $1.3 billion in 2025.
  • Its Operating Expenses was $1.3 billion in Q3 2025, compared to $1.0 billion in Q2 2025 and $1.2 billion in Q1 2025.